AI news ·
Quotient Sciences begins first clinical trial of AI-designed drug formulation
Quotient Sciences has started a Phase I clinical trial of a drug formulation designed by AI, the first such product to reach human testing. The UK study will assess safety and how the oral dose performs in healthy volunteers.
AI-Designed Drug Formulation Enters Clinical Testing
Quotient Sciences has initiated a Phase I clinical study of a drug formulation designed using artificial intelligence, marking what the company says is the first time an AI-designed drug product has reached human testing.
The study launched at Quotient Sciences' UK facility with approval from the Medicines and Healthcare products Regulatory Agency (MHRA). Researchers will evaluate the safety and pharmacokinetics of the oral solid dose formulation in healthy volunteers.
The trial serves a dual purpose: testing the specific drug candidate and validating whether AI can reliably guide formulation design. Machine learning algorithms from Intrepid Labs helped optimize the formulation by rapidly exploring design options and predicting clinical performance.
Faster Decisions, Earlier in Development
Quotient Sciences paired AI-driven design with real-time clinical testing to compress the decision timeline. Product development teams can now evaluate formulation choices with better data earlier in the process, before committing significant resources to full-scale trials.
Andy Lewis, Chief Scientific Officer at Quotient Sciences, said the approach combines machine learning with scientific expertise to "make earlier, more informed decisions with greater confidence, ultimately increasing the likelihood of clinical success."
The company integrated this AI work with its Translational Pharmaceutics platform, which focuses on predicting how drugs will perform in human subjects based on laboratory data.
What Comes Next
Quotient Sciences plans to share clinical data and results over the coming months. The company also intends to expand AI-enabled methods across its broader formulation development and clinical workflows.
For product development professionals, the study demonstrates a concrete use case: AI can reduce the guesswork in formulation design and compress timelines without sacrificing scientific rigor. The validation matters because it shows the technology works in practice, not just in theory.
Learn more about AI for Product Development and AI for Science & Research.